

1 **IS SHORT-TERM ACYCLOVIR TREATMENT RELATED WITH MORE**  
2 **UNFAVOURABLE OUTCOMES IN PATIENTS WITH HSV-1 ENCEPHALITIS?**

3  
4 Ferhat Arslan<sup>1</sup>, Ravza Akgündüz<sup>1</sup>, Abdülkadir Ermiş<sup>2</sup>, Begüm Bektaş<sup>1</sup>, Ebru Erbayat<sup>2</sup>, Haluk  
5 Vahaboğlu<sup>1</sup>

6  
7 1. Department of Infectious Diseases, Istanbul Medeniyet University, Faculty of  
8 Medicine, Istanbul, Turkey

9 2. Department of Neurology, Istanbul Medipol University, Faculty of Medicine,  
10 Istanbul, Turkey

11  
12 **Corresponding author:** Ferhat Arslan, Associate Professor

13 **Email addresses:** [ferhatarlandr@hotmail.com](mailto:ferhatarlandr@hotmail.com)

14 Department of Infectious Diseases, Istanbul Medeniyet University, Faculty of Medicine, Prof.  
15 Dr. Süleyman Yalcın Training and Research Hospital, Kadıköy, Istanbul

16 **Data availability : If request it will be sent to the editors**

17 **Conflicts of Interest and Source of Funding:** Authors have no competing interests to  
18 declare and not received any fund.

19 **Ethics approval statement:** Ethics committee approval was obtained from the ethics  
20 committee of Istanbul Medeniyet University.

21 **Patient consent statement:** In tertiary hospitals at Turkey , all admitted patients sign the  
22 consent form to publish their medical knowledge for scientific purposes.

23

24 **Ferhat Arslan:** Conceptualization, Methodology, Writing- Original draft preparation. **Ravza**  
25 **Akgündüz:** Data curation, Investigation. **Abdülkadir Ermiş:** Data curation ,Investigation.  
26 **Begüm Bektaş:** Data curation: **Ebru Erbayat:** Writing- Reviewing and Editing, **Haluk**  
27 **Vahaboğlu:**Supervision

## 28 **ABSTRACT**

### 29 **Background**

30 Herpes simplex encephalitis (HSE) is the most common form of sporadic encephalitis which  
31 is caused by herpes simplex virus type 1 (HSV-1). Current guidelines recommend intravenous  
32 Acyclovir for 14–21 days in cases of HSE.

### 33 **Objectives**

34 Optimizing the Acyclovir treatment duration is important in regards to preventing Acyclovir-  
35 related neurotoxicity and nephrotoxicity.

### 36 **Study design**

37 We retrospectively evaluated 13 patients, who were diagnosed with HSE by molecular testing  
38 (HSV-1 PCR positivity in cerebrospinal fluid), in two university hospitals in Istanbul,  
39 between 2010 and 2021. The patients were treated either 10 days or less as a short-term  
40 treatment regimen of Acyclovir or for 14 days or more as long-term treatment regimen

41

### 42 **Results**

43 The median age was 58 years (range 24–82 years) and 54% of them were male. The median  
44 follow-up time was 79 days (range 20-670 days) after discharge. Long-term treatment was  
45 used in 6 and a short-term treatment regimen was used in 7 cases. One of the patients died on  
46 the 4th day of Acyclovir treatment. One patient never received Acyclovir treatment. Of the 5  
47 patients who received long-term treatment, 3 (21-28 days) had amnesia and orientation-

48 cooperation restriction, one (21 days) died on the 2nd day of treatment, while the other (14  
49 days) had no sequelae. There were no sequelae in three out of 5 patients who received short-  
50 term treatment.

## 51 **Conclusions**

52 We believe that it is necessary to determine the optimal Acyclovir therapy duration should be  
53 evaluated in a prospective randomized clinical trial in large patient population.

54 **Key words:** Herpes simplex virus ; Encephalitis; Acyclovir; Antiviral treatment; Antivirals

55

## 56 **INTRODUCTION**

57

58 Herpes simplex encephalitis (HSE) is the most common form of sporadic encephalitis which  
59 is caused by herpes simplex virus type 1 (HSV-1). HSV-1 generally infects orolabial mucosa  
60 and face skin epithelium, gains access to neuronal axonal ending, and then is transported to  
61 the trigeminal ganglia (TG)<sup>1</sup>. It is estimated approximately 200 million recurrent HSV-1  
62 related infections develop every year<sup>2</sup>. However, very few of these cases are HSE. The  
63 rareness might be due to its different ways of inoculation in the brain and TG or due to the  
64 primary infection rather than reactivation<sup>3</sup>. Despite the increasing knowledge, there are still  
65 unclear points in the pathogenesis of HSE.

66 Although it was reported that the mortality rates were above 70% and the rates of  
67 neurological sequelae were around 90%, it has now been decreased to 30% for both mortality  
68 and severe neurological sequelae<sup>4</sup>. Mortality rates have decreased significantly by the  
69 discovery of Acyclovir, improvements in radiological screening (cranial magnetic resonance  
70 imaging), and the use of molecular (HSV-1 DNA) diagnostic methods in medical practice.  
71 Vidarabine was used as a comparative drug in two double-blind, randomized controlled  
72 clinical trials investigating the efficacy and side effects of Acyclovir treatment for HSE<sup>5,6</sup>.

73 The duration of Acyclovir treatment was ten days in these trials. However, current guidelines  
74 recommend intravenous Acyclovir for 14–21 days in cases of HSE<sup>7,8</sup>. Optimizing the  
75 Acyclovir treatment duration is important in regards to preventing Acyclovir-related  
76 neurotoxicity and nephrotoxicity<sup>9</sup>. Here, we aimed to discuss the recommended treatment  
77 durations in patients with HSE by using short-term versus long-term acyclovir treatment. We  
78 also emphasize the effects of adjunctive therapies, such as steroids and antibiotics, on these  
79 cases.

## 80 **MATERIALS AND METHODS**

### 81 **Patients**

82

83 We retrospectively evaluated 13 patients, who were diagnosed with HSE by molecular testing  
84 (HSV-1 PCR positivity in cerebrospinal fluid), in two university hospitals in Istanbul,  
85 between 2010 and 2021. Their clinical (altered mental status, seizures or focal neurological  
86 symptoms) and radiological findings (detection of lesions in diffusion or contrast-enhanced  
87 MRI), were analyzed. The patients were treated either 10 days or less as a short-term  
88 treatment regimen of Acyclovir or for 14 days or more as long-term treatment regimen.  
89 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was used for the  
90 assessment of the renal damage for each case.

91 Ethics committee approval was obtained from the ethics committee of Istanbul Medeniyet  
92 University.

93 The neurological status for each case was noted from the outpatient follow-up records.  
94 Neurological sequelae have been defined as any damage to the central nervous system that  
95 results in cognitive, sensory, or motor deficits, which may also manifest as long-term  
96 emotional instability and seizures in severe cases<sup>10</sup>.

97

## 98 RESULTS

99

### 100 Clinical and MRI features

101

102 A summary of the clinical information of 13 patients is shown in **Table 1**.

103 The median age was 58 years (range 24–82 years) and 54% of them were male. The median  
104 follow-up time was 79 days (range 20–670 days) after discharge. Five patients had an  
105 underlying disease-causing immune deficiency: Two had organ tumors (Lung cancer and  
106 prostate cancer, other two patients had Diabetes mellitus, which one of them with febrile  
107 neutropenia due to hemophagocytic syndrome and one patient had recurrent orolabial Herpes  
108 reactivation at the time of the diagnosis. The median duration of diagnosis, starting from the  
109 symptom onset was 5 days (IQR 5 days Q3:8 Q1:3 IQR:5). The CSF analysis showed  
110 lymphocytic pleocytosis in 9/13 patients (median leukocyte count 161 cells/mL, range 0–  
111 500), and elevated protein concentration in 10/13 (median 91 mg/dL, range 35–349)  
112 While unconsciousness was observed in all of the patients, no neck stiffness was found in any  
113 of them. On admission, fever (9/13), headache (9/13), seizures (7/13) and focal neurological  
114 signs (diplopia and hearing loss in 1 patient and right hemiparesis in another patient) were  
115 noted.

116 In all patients, the clinical diagnosis of HSE was confirmed by the MRI findings of unilateral  
117 (9 patients) or bilateral (3 patients) increased fluid-attenuated inversion recovery (FLAIR)/T2  
118 signal abnormalities in temporal regions. In five patients, frontal (2 patients), hippocampal (2  
119 patients) and occipital (1 patient) FLAIR/T2 signal abnormalities were additionally observed.

120

### 121 Treatment

122 Long-term treatment was used in 6 and a short-term treatment regimen was used in 7 cases.  
123 One of the patients died on the 4th day of Acyclovir treatment. One patient never received  
124 Acyclovir treatment. Twelve patients had also broad-spectrum antibiotic treatment at the  
125 beginning. Adjunctive steroid therapy was given in 3 patients. Antiepileptic therapy was  
126 needed for 10 patients. Treatment modalities and follow-up of renal functions are summarized  
127 in **Table 2**

## 128 **Outcomes**

129

130 Death occurred in 2 patients. One of them was already on severe immunosuppressive therapy  
131 due to EBV-related hemophagocytosis. The other patient had lung cancer with brain  
132 metastases and subarachnoid hemorrhage. Of the 5 patients who received long-term treatment,  
133 3 (21-28 days) had amnesia and orientation-cooperation restriction, one (21 days) died on the  
134 2nd day of treatment, while the other (14 days) had no sequelae. There were no sequelae in  
135 three out of 5 patients who received short-term treatment, however, balance problems  
136 continued in one of them in 6 months after treatment. Neurological sequelae did not develop  
137 in the patient who did not receive any treatment. CKD-EPI decrease associated with renal  
138 failure was seen only in one patient.

139

## 140 **DISCUSSION**

141

142 There is a solid consensus for the early initiation of effective antiviral agents in HSE,  
143 however, recommendations regarding the duration of the antiviral treatment is still at the level  
144 of expert opinion. Although this is a case series study and it is consisted of a small number of  
145 cases, we observed some interesting results: In short term Acyclovir treatment group, CNS  
146 symptoms of all 6 patients improve within the first week of the drug discontinuation, contrary

147 to the long-term treatment group, where the symptoms and signs of the HSE continued after  
148 the discontinuation. In another word, neurological sequelae in long-term treatment group were  
149 more common than the short-term treatment group. Additionally, the patients who received  
150 steroid treatments from both groups (patient 1,6,7,10) did not reveal any neurological  
151 deterioration. Seizure in one patient in 26th month and progressive amnesia in another patient  
152 on 5th month of the follow-up after short term treatment, respectively. Interestingly,  
153 neurological sequelae did not develop in the patient (patient 2 who was not given acyclovir  
154 treatment. One out of patients were treated with empirical antibiotics. Our observations may  
155 encourage steroid and short-term Acyclovir therapy in the management of the patients with  
156 HSE.

157

158 Stevens et al. showed that HSV viral replication continued for up to 8 days in a spinal  
159 ganglion of animal model study<sup>11</sup>. In a superior cervical ganglia (SCG) cell cultures-based  
160 HSV-1 model study, it was shown that phase 1 and phase 2 transcriptional processes take  
161 place in less than 5 days<sup>12</sup>. Toll like receptor 3 (TLR-3) dependent production of IFN- $\alpha/\beta$  and  
162 IFN- $\lambda$  is seen as a protective factor for HSE in children<sup>13</sup>. Additionally, Acyclovir doesn't  
163 have an inhibitor effect on the replication of the HSV-1 in human neural cell lines without  
164 human interferon-alpha (IFN-alpha)<sup>14</sup>. IFN- $\beta$  treatment in baby mice with HSV encephalitis  
165 model decreased neuro-invasion and increase the survival rate<sup>15</sup>. We may conclude that the  
166 combined effect of Acyclovir implementation and host interferon response can be achieved  
167 only at the early days of the HSE. In our study, the median time from symptoms onset to  
168 treatment initiation was 3.4 days in the group receiving short-term acyclovir treatment, while  
169 it is 6.6 days in the group receiving long-term treatment. This may contribute to the low rate  
170 of neurological sequelae in the group receiving short-term treatment.

171 Other probable justifications have been put forward for long-term antiviral treatment  
172 rationale. In situ low-level HSV-1 replication hypothesis examined in the prospective  
173 randomized double-blind study of Gnann et al, long-term Valacyclovir treatment was found to  
174 have no significant effect on neurological outcome<sup>16</sup>. The second issue is the assumed  
175 virological relapse that may be seen after the early cessation of acyclovir. In a long-term study  
176 of 32 adult HSE cases prospectively observed, HSE relapse was reported in 4 patients.  
177 However, HSV PCR positivity was not detected in any of the 12 CSF samples taken from  
178 these patients. It has been reported that putative relapses occur within the first 4 months after  
179 infection<sup>17</sup>. It was reported that HSV-1 antigen and HSV-1 DNA were detected  
180 immunohistochemically in the necrotic right frontal and parietal lobe samples from the  
181 autopsy of a patient who presented with status epilepticus 5 years after HSE<sup>18</sup>. The authors  
182 claim that this case is the first pathologically and molecularly confirmed relapse of HSE in the  
183 medical literature. However, progressive neurological deterioration throughout 5 years in the  
184 course of the case raises questions about whether the patient is in a relapse or a chronic  
185 autoimmune process<sup>19,20</sup>.

186 During the SARS-CoV-2 pandemic, there has been increased awareness about the possible  
187 antiviral effects of some drugs that are not used as virucidal<sup>21</sup>. Empirical antibiotics and  
188 steroids along with the Acyclovir treatment is a quite common clinical approach to the HSE  
189 cases in the first days before definitive diagnosis<sup>22</sup>. Inhibitory activity of Cephalosporin  
190 derivatives on HSV-1 was shown in vitro<sup>23</sup>. Similarly, some other molecules (Valproic acid,  
191 Valpromide and Valnoctamide) that inhibit the replication of HSV-1 virus in  
192 oligodendrocytes have been identified<sup>24</sup>. The researchers emphasized that these molecules  
193 could be an effective and safe treatment alternatives in HSE. The effect of non-antiviral drugs,  
194 especially antibiotics on HSE prognosis has not been studied.

195 Researchers have developed human induced pluripotent stem cells (hiPSCs) and neuronal  
196 cells based on 3D organoid models to establish HSV-1 infections<sup>25</sup>. Although in vitro  
197 establishment of neuron cells infection has been shown, there are in vivo differences. HSV-1  
198 has evolved latency mechanisms to stay in neuron cells in order to escape from immunity<sup>26</sup>.  
199 Due to the logic of co-evolution, the relationship between HSV and neuronal cells cannot be  
200 considered to be direct damage (cytopathic damage). The important question here is which  
201 cells are susceptible for HSV-1 replication in brain<sup>27</sup>. As we understand from the CSF finding,  
202 erythrocytosis, the blood-brain barrier (BBB) is disrupted in HSE patients<sup>28</sup>. Brain  
203 microvascular endothelial cells may play the primary role in neuronal damage due to HSV-1  
204 induced endothelial cell adhesion molecules that interact with lymphocytes and neutrophils  
205 recruitment<sup>29,30</sup>. We may speculate that steroids may play a role to diminish this recruitment  
206 and decrease the vascular inflammation as adjunctive therapy. Adjunctive steroid therapy  
207 initiation timing and its duration are still elusive<sup>31</sup>.

208 In conclusion, the optimal duration of antiviral treatment for HSE is still a controversial issue.  
209 Those who received short-term treatment might not have worse outcome than those who  
210 received long-term treatment in terms of neurological sequelae. We believe that it is necessary  
211 to determine the optimal Acyclovir therapy duration, as well as the steroids' effect on  
212 probable vasculitis and should be tested in a prospective randomized clinical trial in large  
213 patient population.

214

215

216

217

## 218 REFERENCES

- 219 1. Sawtell NM, Thompson RL. Alphaherpesvirus Latency and Reactivation with a Focus  
220 on Herpes Simplex Virus. *Curr Issues Mol Biol.* 2020;41:267-356.  
221 doi:10.21775/cimb.041.267
- 222 2. James C, Harfouche M, Welton NJ, et al. Herpes simplex virus: global infection  
223 prevalence and incidence estimates, 2016. *Bull World Health Organ.* 2020;98(5):315-  
224 329. doi:10.2471/BLT.19.237149
- 225 3. Steiner I. Herpes simplex virus encephalitis: new infection or reactivation? *Curr Opin*  
226 *Neurol.* 2011;24(3):268-274. doi:10.1097/WCO.0b013e328346be6f
- 227 4. McGrath N, Anderson NE, Crosson MC, Powell KF. Herpes simplex encephalitis  
228 treated with acyclovir: diagnosis and long term outcome. *J Neurol Neurosurg*  
229 *Psychiatry.* 1997;63(3):321-326. doi:10.1136/jnnp.63.3.321
- 230 5. Sköldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes  
231 simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.  
232 *Lancet Lond Engl.* 1984;2(8405):707-711. doi:10.1016/s0140-6736(84)92623-0
- 233 6. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes  
234 simplex encephalitis. *N Engl J Med.* 1986;314(3):144-149.  
235 doi:10.1056/NEJM198601163140303
- 236 7. Tunkel AR, Glaser CA, Bloch KC, et al. The Management of Encephalitis: Clinical  
237 Practice Guidelines by the Infectious Diseases Society of America. *Clin Infect Dis.*  
238 2008;47(3):303-327. doi:10.1086/589747
- 239 8. Solomon T, Michael BD, Smith PE, et al. Management of suspected viral encephalitis in  
240 adults – Association of British Neurologists and British Infection Association National  
241 Guidelines. *J Infect.* 2012;64(4):347-373. doi:10.1016/j.jinf.2011.11.014
- 242 9. Adair JC, Gold M, Bond RE. Acyclovir neurotoxicity: clinical experience and review of  
243 the literature. *South Med J.* 1994;87(12):1227-1231. doi:10.1097/00007611-199412000-  
244 00006
- 245 10. Ronca SE, Dineley KT, Paessler S. Neurological Sequelae Resulting from Encephalitic  
246 Alphavirus Infection. *Front Microbiol.* 2016;7:959. doi:10.3389/fmicb.2016.00959
- 247 11. Stevens JG, Cook ML. Latent herpes simplex virus in spinal ganglia of mice. *Science.*  
248 1971;173(3999):843-845. doi:10.1126/science.173.3999.843
- 249 12. Kim JY, Mandarino A, Chao MV, Mohr I, Wilson AC. Transient reversal of episome  
250 silencing precedes VP16-dependent transcription during reactivation of latent HSV-1 in  
251 neurons. *PLoS Pathog.* 2012;8(2):e1002540. doi:10.1371/journal.ppat.1002540
- 252 13. Lafaille FG, Pessach IM, Zhang S-Y, et al. Impaired intrinsic immunity to HSV-1 in  
253 human iPSC-derived TLR3-deficient CNS cells. *Nature.* 2012;491(7426):769-773.  
254 doi:10.1038/nature11583

- 255 14. Hanada N, Kido S, Kuzushima K, Goto Y, Rahman MM, Morishima T. Combined  
256 effects of acyclovir and human interferon-alpha on herpes simplex virus replication in  
257 cultured neural cells. *J Med Virol*. 1989;29(1):7-12. doi:10.1002/jmv.1890290103
- 258 15. Giraldo D, Wilcox DR, Longnecker R. The Innate Immune Response to Herpes Simplex  
259 Virus 1 Infection Is Dampened in the Newborn Brain and Can Be Modulated by  
260 Exogenous Interferon Beta To Improve Survival. *mBio*. 2020;11(3).  
261 doi:10.1128/mBio.00921-20
- 262 16. Gnann JW Jr, Sköldenberg B, Hart J, et al. Herpes Simplex Encephalitis: Lack of  
263 Clinical Benefit of Long-term Valacyclovir Therapy. *Clin Infect Dis*. 2015;61(5):683-  
264 691. doi:10.1093/cid/civ369
- 265 17. Sköldenberg B, Aurelius E, Hjalmarsson A, et al. Incidence and pathogenesis of clinical  
266 relapse after herpes simplex encephalitis in adults. *J Neurol*. 2006;253(2):163-170.  
267 doi:10.1007/s00415-005-0941-6
- 268 18. Yamada S, Kameyama T, Nagaya S, Hashizume Y, Yoshida M. Relapsing herpes  
269 simplex encephalitis: pathological confirmation of viral reactivation. *J Neurol*  
270 *Neurosurg Psychiatry*. 2003;74(2):262-264. doi:10.1136/jnnp.74.2.262
- 271 19. Schein F, Gagneux-Brunon A, Antoine J-C, et al. Anti-N-methyl-D-aspartate receptor  
272 encephalitis after Herpes simplex virus-associated encephalitis: an emerging disease  
273 with diagnosis and therapeutic challenges. *Infection*. 2017;45(4):545-549.  
274 doi:10.1007/s15010-016-0959-y
- 275 20. Armangue T, Leypoldt F, Málaga I, et al. Herpes simplex virus encephalitis is a trigger  
276 of brain autoimmunity. *Ann Neurol*. 2014;75(2):317-323.  
277 doi:https://doi.org/10.1002/ana.24083
- 278 21. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map  
279 reveals targets for drug repurposing. *Nature*. 2020;583(7816):459-468.  
280 doi:10.1038/s41586-020-2286-9
- 281 22. Hagen A, Eichinger A, Meyer-Buehn M, Schober T, Huebner J. Comparison of  
282 antibiotic and acyclovir usage before and after the implementation of an on-site  
283 FilmArray meningitis/encephalitis panel in an academic tertiary pediatric hospital: a  
284 retrospective observational study. *BMC Pediatr*. 2020;20(1):56. doi:10.1186/s12887-  
285 020-1944-2
- 286 23. Cottagnoud P, Neftel KA, Hany M, Zinkernagel RM. Inhibition of HSV-1 and vaccinia  
287 virus replication by cephalosporin derivatives. *Antiviral Res*. 1988;10(1):59-70.  
288 doi:10.1016/0166-3542(88)90014-9
- 289 24. Praena B, Bello-Morales R, de Castro F, López-Guerrero JA. Amidic derivatives of  
290 valproic acid, valpromide and valnoctamide, inhibit HSV-1 infection in  
291 oligodendrocytes. *Antiviral Res*. 2019;168:91-99. doi:10.1016/j.antiviral.2019.05.006
- 292 25. D’Aiuto L, Bloom DC, Naciri JN, et al. Modeling Herpes Simplex Virus 1 Infections in  
293 Human Central Nervous System Neuronal Cells Using Two- and Three-Dimensional  
294 Cultures Derived from Induced Pluripotent Stem Cells. *J Virol*. 2019;93(9).  
295 doi:10.1128/JVI.00111-19

- 296 26. Kalamvoki M, Du T, Roizman B. Cells infected with herpes simplex virus 1 export to  
 297 uninfected cells exosomes containing STING, viral mRNAs, and microRNAs. *Proc Natl*  
 298 *Acad Sci U S A*. 2014;111(46):E4991-4996. doi:10.1073/pnas.1419338111
- 299 27. Bello-Morales R, Fedetz M, Alcina A, Tabarés E, López-Guerrero JA. High  
 300 susceptibility of a human oligodendroglial cell line to herpes simplex type 1 infection. *J*  
 301 *Neurovirol*. 2005;11(2):190-198. doi:10.1080/13550280590924179
- 302 28. Liu H, Qiu K, He Q, Lei Q, Lu W. Mechanisms of Blood-Brain Barrier Disruption in  
 303 Herpes Simplex Encephalitis. *J Neuroimmune Pharmacol Off J Soc NeuroImmune*  
 304 *Pharmacol*. 2019;14(2):157-172. doi:10.1007/s11481-018-9821-6
- 305 29. Brankin B, Hart MN, Cosby SL, Fabry Z, Allen IV. Adhesion molecule expression and  
 306 lymphocyte adhesion to cerebral endothelium: effects of measles virus and herpes  
 307 simplex 1 virus. *J Neuroimmunol*. 1995;56(1):1-8. doi:10.1016/0165-5728(94)00110-a
- 308 30. Michael BD, Bricio-Moreno L, Sorensen EW, et al. Astrocyte- and Neuron-Derived  
 309 CXCL1 Drives Neutrophil Transmigration and Blood-Brain Barrier Permeability in  
 310 Viral Encephalitis. *Cell Rep*. 2020;32(11):108150. doi:10.1016/j.celrep.2020.108150
- 311 31. Piret J, Boivin G. Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis.  
 312 *Clin Microbiol Rev*. 2020;33(2). doi:10.1128/CMR.00105-19
- 313

314 **TABLE 1: CLINICAL FEATURES OF PATIENTS WITH HERPES SIMPLEX ENCEPHALITIS (HSE) WHO**  
 315 **RECIEVED ACYCLOVIR TREATMENT**  
 316  
 317

	Age range /Sex	Symptoms	Signs	Cranial MRI findings	CSF PCR	Time to Treatment <sup>a</sup>	Outcome
<b>Patient 1</b>	(50-55)/F	Altered mental status, dysarthria, behavioral changes	Confused, disoriented, limited cooperation	Bilateral insular cortex, right temporal lobe, contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	1 day	No sequelae alive
<b>Patient 2</b>	(80-85)/M	Fever, headache	Lethargy	Right temporal lobe, hippocampal, insular cortex contrast enhancement, and diffusion restriction	CSF HSV Type-1 PCR: Positive	None	No sequelae alive
<b>Patient 3</b>	(75-80)/F	Altered mental status, dysarthria, difficulties on walking	Unconscious GCS=10	Bilateral temporal lobe (right dominant), contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	3 days	No sequelae alive

<b>Patient 4</b>	(40-45)/M	Altered mental status, dysarthria, fever, headache, nausea and vomiting, loss of balance	Confused, disoriented, limited cooperation	Right temporal lobe, parasylvian, hippocampal and parahippocampal contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	7 days	No sequelae alive
<b>Patient 5</b>	(65-70)/F	Fever, Headache, Dysarthria	Confused, disoriented, limited cooperation	Left temporal lobe, hippocampal, insular cortex contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	5 days	No sequelae alive
<b>Patient 6</b>	(20-25)/F	Fever, headache, altered mental status, nausea and vomiting	Confused, disoriented, limited cooperation	Left temporal lobe, left insular cortex, uncut and hippocampus gyrus, dorsal thalamus contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	3 days	Loss of balance, seizures alive
<b>Patient 7</b>	(65-70)/M	Altered mental status, convulsion	Confused, disoriented, limited cooperation	Right temporal lobe, insular cortex T2 hyperintensity and diffusion restriction	CSF HSV Type-1 PCR: Positive	5 days	Dead
<b>Patient 8</b>	(20-25)/F	Fever, Headache, Seizure	Lethargy	Right temporal lobe, insular cortex, thalamus contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	3 days	No sequelae alive
<b>Patient 9</b>	(70-75)/M	Altered mental status, headache, vesicular rash	Lethargy	Normal	CSF HSV Type-1 PCR: Positive	10 days	Dead
<b>Patient 10</b>	(40-45)/M	Altered mental status, Fever, Decreased hearing,	Confused, disoriented, Lethargy diplopia	Right Frontotemporal lobe, T2 hyperintensity	CSF HSV Type-1 PCR: Positive	7 days	Dead
<b>Patient 11</b>	(60-65)/F	Altered mental status, Convulsion, Fever, Headache	Confused, disoriented, limited cooperation	Left temporal lobe, insular cortex, contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	8 days	Confused, loss of time orientation, alive

<b>Patient 12</b>	(65-70)/M	Altered mental status, Fever, Convulsion	Confused, disoriented, limited cooperation	Bilateral temporal lobe (right dominant), Right thalamus contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	4 days	Confused, prolonged reaction time to complex orders, alive
<b>Patient 13</b>	(60-65)/M	Altered mental status, Headache, behavioral changes	Confused, disoriented, limited cooperation sensory aphasia	Right Fronto-temporal lobe, contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	8 days	Confused, disoriented, alive

318 <sup>a</sup>: Time from symptoms onset to treatment initiation

319

320

321

322

323

324

325

326

327

328

329

330

331

332

**TABLE 2: TREATMENT MODALITIES AND RENAL FUNCTIONS OF PATIENTS WITH HERPES SIMPLEX ENCEPHALITIS (HSE)**

<b>Patients</b>	<b>Empirical antibiotics</b>	<b>Acyclovir start time <sup>a</sup></b>	<b>Acyclovir duration</b>	<b>Steroid treatment</b>	<b>Antiepileptic treatment</b>	<b>CNS Symptoms resolved time</b>	<b>eGFR(CKD-EPI) on admission</b>	<b>eGFR(CKD-EPI) on discharge</b>
Patient 1	Cefuroxime axetil, Meropenem- Linezolid-INH- Rifampin	1 d	10 d	2 d	1 months after discharge	3 days (AAS)	97	86
Patient 2	Meropenem Linezolid	None	None	None	None	14th days of admission	45	76
Patient 3	Ampicillin	3 d	9 d	None	5 months after discharge	9 days (AAS)	36	55
Patient 4	Ceftriaxone	1 d	7 d	None	2 months after discharge	4 days (AAS)	117	68

Patient 5	Amoxicilline-Clavulanate, Ampicillin-Ceftriaxone	5 d	7 d	None	None	4 days (AAS)	83	55
Patient 6	Ceftriaxone Ampicilline	1 d	10 d	7 d + 20 d	2nd day of hospitalization	3 days (ASI)	127	134
Patient 7	Piperacilline-Tazobactam	5 d	4 d	None	2nd day of symptoms	None	100	112
Patient 8	Ceftriaxone	1 d	14 d	3 d	2nd day of hospitalization	10th days of admission	131	123
Patient 9	Ceftriaxone	1 d	21 d	None	None	12th days of admission	85	82
Patient 10	meropenem	7 d	21 d	10 d	None	14 days (AAS)	70	36
Patient 11	Ceftriaxone	8 d	28 d	None	1st day of hospitalization	5 days (AAS), but confusion permanent	74	95

Patient 12	Ceftriaxone and levofloxacin	4 d	24 d	None	1st day of hospitalization	7 days (AAS) but confusion permanent	81	102
Patient 13	None	8 d	21 d	None	3rd day of hospitalization	3 days (AAS)	72	62

<sup>a</sup> : Time from symptoms onset to treatment initiation

CNS: Central nervous system; AAS: After acyclovir stopped; ASI: After steroid initiation